EQRx Resets to Focus on Clinically Differentiated Medicines, Leveraging $1.3 Billion Cash Position

EQRx, Inc. (Nasdaq: EQRX), recently announced plans to reset its business and reported financial results for the first quarter ended March 31, 2023.